ArticleAntimicrobial agents and chemotherapy2014
Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.The Journal of infection · 2018Trial
- Antifungal Management in Patients with Hematological Malignancies: From Primary Prophylaxis to Empirical and Diagnosis-Driven TreatmentTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Review
- What Is the Prognostic Significance of Culture-Documented Breakthrough Invasive Pulmonary Aspergillosis in Patients with Hematological Malignancies? A Propensity Score-Adjusted Analysis.Journal of fungi (Basel, Switzerland) · 2025Article
- High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies.Microorganisms · 2024Review
- Antifungal prophylaxis with nebulized amphotericin-B in solid-organ transplant recipients with severe COVID-19: a retrospective observational study.Frontiers in cellular and infection microbiology · 2023Observational
- Sphingosine as a New Antifungal Agent againstInternational journal of molecular sciences · 2022Article
- Liposomal amphotericin B-the future.The Journal of antimicrobial chemotherapy · 2022Article
- Loss of Septation Initiation Network (SIN) kinases blocks tissue invasion and unlocks echinocandin cidal activity against Aspergillus fumigatus.PLoS pathogens · 2021Article
- Breakthrough Invasive Fungal Infections in Patients with Acute Myeloid Leukemia.Mycopathologia · 2020Article
- Deciphering the Relationship Between the Trough Concentration of Posaconazole and Its Efficacy and Safety in Chinese Patients With Hematological Disorders.Frontiers in pharmacology · 2020Article
- Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.Antimicrobial agents and chemotherapy · 2019Review
- Extended Dosing Regimens for Fungal Prophylaxis.Clinical microbiology reviews · 2019Review
- Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy.Open forum infectious diseases · 2019Article
- Breakthrough Invasive Mold Infections in the Hematology Patient: Current Concepts and Future Directions.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.The Journal of antimicrobial chemotherapy · 2018Review
- Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Drugs · 2014Review
- Reply to "Risk for invasive fungal infections during acute myeloid leukemia induction therapy: a true association with echinocandins?".Antimicrobial agents and chemotherapy · 2014Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although antifungal prophylaxis is frequently administered to patients with acute myeloid leukemia (AML) during remission-induction chemotherapy (RIC), its impact on reducing invasive fungal infections (IFIs) outside clinical trials is rarely reported. We performed a retrospective observational study to identify risk factors for development of IFIs (definite or probable, using revised European Organization for Research and Treatment of Cancer [EORTC] criteria) and all-cause mortality in a cohort of 152 AML patients receiving RIC (2009 to 2011). We also compared rates of IFI and mortality in patients who received echinocandin versus anti-Aspergillus azole (voriconazole or posaconazole) prophylaxis during the first 120 days of RIC. In multivariate analysis, clofarabine-based RIC (hazard ratio [HR], 3.5; 95% confidence interval [CI], 1.5 to 8.3; P = 0.004) and echinocandin prophylaxis (HR, 4.6; 95% CI, 1.8 to 11.9; P = 0.002) were independently associated with higher rates of IFI rates during RIC. Subsequent analysis failed to identify any malignancy- or chemotherapy-related covariates linked to echinocandin prophylaxis that accounted for the higher rates of breakthrough IFI. Although the possibility of other confounding variables cannot be excluded, our findings suggest that echinocandin-based prophylaxis during RIC for AML may be associated with a higher risk of breakthrough IFI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.